BIOMARIN PHARMACEUTICAL INC. STIFEL 2026 HEALTHCARE CONFERENCE - AMICUS THERAPEUTICS INC

Financial Performance:

• Achieved record Q3 total revenue of $1 billion, representing 32% year-over-year growth.
• The Metabolics Conditions business unit drove 44% growth, specifically fueled by the Amicus Therapeutics acquisition (Gallifld, Pompity, Opfolda).
• Amicus-specific assets showed double-digit growth; Gallifld grew 20% in a specific market, while Pompity and Opfolda grew nearly 60%.
• Two acquisitions in Q3 incurred in-process R&D expenses, temporarily impacting earnings but expected to be highly accretive long-term.
• Projected to achieve 50% operating expense synergies (approx. $220 million annually) by 2028, enabling the Amicus business to reach a ~60% operating margin by the end of the decade.
• Company is actively deleveraging with a target debt-to-EBITDA ratio of less than 2.5x by mid-2028; current deals funded via cash on hand.

Guidance and Future Outlook:

• Targeting full integration of Amicus assets by mid-2028, with a healthy inflection in profitability expected thereafter.
• VoxOgo (BMN 333) Phase 2 data readout expected in 2027 for hypochondroplasia, following approval for achondroplasia.
• BMN 820 (FSGS) Phase 3 study results anticipated in 2028, utilizing proteinuria reduction as the primary endpoint.
• 2027 operating plan guidance will likely reflect a second-half ramp for the Hypochondroplasia launch (PDUFA May 30th) but may not fully quantify it due to label uncertainty.
• Management plans to maintain focus on clinical-stage assets and deleveraging before committing to larger M&A (>$1 billion) transactions.

Business Segments and Product Lines:

• Metabolics Conditions: Core growth engine; expanded portfolio with Amicus assets covering Fabry (Gallifld), Pompe (Pompity, Opfolda), and RCD.
• Pipeline Expansion: Added four new assets this year:
  • BMN 450 (Fabry): First potential subcutaneous enzyme replacement therapy (mutation-agnostic), aiming to address patients not eligible for current IV therapies.
  • BMN 440 (Hypophosphatasia): First potential oral substrate reduction therapy targeting ENPP1, aiming to treat muscle and joint symptoms beyond bone mineralization.
  • BMN 430: Preclinical program for RCD syndrome.
  • BMN 820 (FSGS): Partnered asset (US rights) targeting macrophage-driven inflammation as an oral alternative to vascular agents.
• VoxOgo (Voxelotor): Expanding into hypochondroplasia; Phase 2 study for BMN 333 includes internal controls and Bayesian modeling to assess superiority over current standards.

Market and Competitive Landscape:

• Hypophosphatasia: Current treatment (Strensiq) has low penetration in adults (10-30%); BMN 440 targets unmet needs regarding pain and joint issues in adult phenotypes.
• Fabry: Galifld addresses only 35-50% of patients (mutation-specific); BMN 450 targets the mutation-agnostic population, potentially replacing IV treatments with subcutaneous delivery.
• Achondroplasia/Hypochondroplasia: BMN 333 aims for a higher efficacy profile by targeting the upper end of the dose-response curve (2-5x cyclic GMP increase) compared to competitor UVL, addressing safety concerns (hypotension) via a longer half-life (99 hours vs. 1 hour).
• FSGS: Aiming to capture patients with nephrotic syndrome using an orthogonal mechanism (CCR2 inhibition) distinct from current vascular-targeting agents, potentially avoiding black box warnings.

Risks and Challenges:

• Integration Risk: Amicus deal integration involves complex synergy realization; delays could impact the 2028 margin targets.
• Clinical Development: Uncertainty in Phase 2/3 endpoint validation for Hypophosphatasia (adult phenotypes) and Achondroplasia (superiority vs. non-inferiority); potential for heterogeneous patient response in FSGS.
• Diagnostic Barriers: Hypochondroplasia faces lower diagnosis rates compared to achondroplasia, requiring significant efforts to identify and enroll patients.
• Debt Levels: Current leverage from the Amicus acquisition limits immediate capacity for billion-plus acquisitions until cash flow and synergies mature.

Management Commentary and Tone:

• Tone is confident and strategic, emphasizing execution on financial strength to fund innovation.
• Management highlighted a "rebuilding of the pipeline" as a core objective, successfully adding four distinct assets in one year.
• Confident in the biological rationale for BMN 440 and BMN 333, citing preclinical and early clinical data supporting substrate reduction and dose-response theories.
• Acknowledged challenges in adult Hypophosphatasia treatment and Hypochondroplasia diagnosis but framed them as solvable through specific molecule properties and commercial infrastructure.

Analyst Questions and Answers:

• Hypophosphatasia (BMN 440): Clarified that the therapy targets pyrophosphate production (substrate reduction) rather than replacement; 30-50% reduction is the target for clinical benefit. Data on PK/PD expected next year.
• Fabry (BMN 450): Confirmed subcutaneous delivery and mutation-agnostic nature; development path will include switching studies and early biomarkers (lyso-Gb3) to bypass long kidney biopsy waits.
• VoxOgo (BMN 333): Discussed study design using internal controls and Bayesian modeling to prove superiority; addressed safety concerns regarding hypotension by highlighting reduced C-max due to longer half-life.
• Hypochondroplasia Launch: Noted a headwind of lower diagnosis rates vs. achondroplasia but a tailwind from established skeletal dysplasia centers; 2027 data readout expected.
• M&A Strategy: Prioritized deleveraging and pipeline building; no immediate plans for >$1B deals until synergies are realized and debt targets met.

Other Key Points:

• Amicus assets are described as "high-growth rare disease assets" that fit the Metabolics Conditions portfolio perfectly.
• BMN 450's subcutaneous formulation offers significant convenience over current IV standards for Fabry patients.
• Regulatory pathways for FSGS now accept 2-year proteinuria reduction as an endpoint for full approval.
• The company remains committed to its "value commitment" objectives, balancing growth, innovation, and financial discipline.